SAN DIEGO--(BUSINESS WIRE)--Nexus Dx Inc., founded in 2009 to consolidate technologies focused on point-of-care (POC) blood diagnostic testing, has named Gordon Sangster as the Company’s new V.P. of Finance and Chief Financial Officer (CFO), effective immediately. As a key member of the Nexus Dx executive leadership team, Sangster will be actively involved in overall financial management, corporate strategic planning, business process improvement and corporate administration. He will report to Nexus Dx President and Chief Executive Officer, Jim Merselis.
Sangster previously served as CFO of Micrus® Endovascular Corporation (NASDAQ: MEND), a company that developed, manufactured and marketed devices for treatment of cerebral vascular diseases, and was recently acquired by Johnson and Johnson. Sangster also served as CFO of POC blood diagnostics company HemoSense prior to its acquisition by Alere. He is an active member of the Institute of Chartered Accountants in England and Wales.
“The addition of Gordon Sangster to the Nexus Dx management team is a significant step forward in the company’s aggressive growth strategy, as it positions itself as a leader in the POC diagnostic industry,” said Merselis. “Gordon is an experienced public company CFO with a distinguished record of achievement in creating and maintaining stakeholder value. His personal and professional expertise will drive corporate growth and performance in this rapidly evolving market.”
Nexus Dx key executives have substantial business, medical and technology experience in the POC sector. The recent Nexus Dx acquisition of International Technidyne Corporation, a global leader in the field of hemostasis management and POC testing, exemplifies the organization’s ongoing successful and active roll-up strategy for corporate business development.
About Nexus Dx
Nexus Dx was formed in 2009 by Bay City Capital to take advantage of current and emerging market opportunities in POC diagnostics by consolidating products and technologies to create a company dedicated to improving patient outcomes and healthcare economics via decentralized blood diagnostic testing. In November, 2010, the Company and International Technidyne Corporation, a global leader in the fields of hemostasis management and POC testing were acquired by Warburg Pincus and merged into the current Nexus Dx organization. This transaction is the latest success in the active roll-up model established by the Company’s executive team.
Nexus Dx is led by Jim Merselis, President and CEO, and Ed Brennan, Ph.D., Chief Integration Officer. Both have over 30 years of experience in the healthcare industry and were formerly CEO and Chairman, respectively, of HemoSense, Inc. (AMEX: HEM) sold in November 2007 to Inverness Medical Innovations (now Alere) for $265 million. Alex Bourdon is the current Vice President of Operations and John Erickson is Chief Commercial Officer for the Company. Both have previously held executive leadership positions within the healthcare industry. Nexus Dx is backed by an investor syndicate consisting of Bay City Capital, Kleiner Perkins Caufield & Byers, Prolog Ventures and Warburg Pincus,. For more information, please visit http://www.nexus-dx.com.